Inactive Instrument

Highlights Pain Therapeutics, Inc. Nasdaq

Equities

US69562K1007

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 25	Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	MT
Mar. 25	Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	Mar. 25	MT
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	Mar. 25	CI
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia	Feb. 07	CI
Cassava Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer?S Disease	Nov. 06	CI
Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients	23-10-25	CI
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer?s Disease	23-10-02	CI
Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer?s Disease	23-09-18	CI
Cassava Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study	23-07-05	CI
Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging	23-06-27	CI
Cassava Sciences Completes Patient Dosing in A Randomized Controlled Trial of Simufilam in Alzheimer’S Disease	23-05-11	CI
Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-01	CI
Cassava Sciences Posts Wider Q4 Loss	23-02-28	MT
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28	CI
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Cassava Sciences, Inc. Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease	23-02-08	CI
Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease	23-01-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pain Therapeutics, Inc. Nasdaq

Equities

US69562K1007

Highlights

Filters